vs
Orthofix Medical Inc.（OFIX）与Pebblebrook Hotel Trust（PEB）财务数据对比。点击上方公司名可切换其他公司
Pebblebrook Hotel Trust的季度营收约是Orthofix Medical Inc.的1.6倍（$345.7M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -5.3%，领先4.3%），Pebblebrook Hotel Trust同比增速更快（7.9% vs 2.0%），Pebblebrook Hotel Trust自由现金流更多（$114.5M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -6.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Pebblebrook Hotel Trust是一家公开上市的房地产投资信托，主要在美国核心城市及休闲目的地持有、运营并投资高端、奢华及精品酒店物业，服务商务与休闲旅客，聚焦高需求市场以推动长期价值增长。
OFIX vs PEB — 直观对比
营收规模更大
PEB
是对方的1.6倍
$219.9M
营收增速更快
PEB
高出6.0%
2.0%
净利率更高
OFIX
高出4.3%
-5.3%
自由现金流更多
PEB
多$97.7M
$16.8M
两年增速更快
OFIX
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $345.7M |
| 净利润 | $-2.2M | $-18.4M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 2.3% |
| 净利率 | -1.0% | -5.3% |
| 营收同比 | 2.0% | 7.9% |
| 净利润同比 | 92.4% | 31.8% |
| 每股收益（稀释后） | $-0.05 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPEB
| Q1 26 | — | $345.7M | ||
| Q4 25 | $219.9M | $349.0M | ||
| Q3 25 | $205.6M | $398.7M | ||
| Q2 25 | $203.1M | $407.5M | ||
| Q1 25 | $193.6M | $320.3M | ||
| Q4 24 | $215.7M | $337.6M | ||
| Q3 24 | $196.6M | $404.5M | ||
| Q2 24 | $198.6M | $397.1M |
净利润OFIXPEB
| Q1 26 | — | $-18.4M | ||
| Q4 25 | $-2.2M | $-17.9M | ||
| Q3 25 | $-22.8M | $-33.1M | ||
| Q2 25 | $-14.1M | $18.1M | ||
| Q1 25 | $-53.1M | $-32.9M | ||
| Q4 24 | $-29.1M | $-50.5M | ||
| Q3 24 | $-27.4M | $43.7M | ||
| Q2 24 | $-33.4M | $30.9M |
毛利率OFIXPEB
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXPEB
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.2% | 2.5% | ||
| Q3 25 | -8.3% | -2.6% | ||
| Q2 25 | -7.9% | 12.9% | ||
| Q1 25 | -25.2% | -2.3% | ||
| Q4 24 | -5.3% | -6.7% | ||
| Q3 24 | -9.6% | 11.6% | ||
| Q2 24 | -12.5% | 15.4% |
净利率OFIXPEB
| Q1 26 | — | -5.3% | ||
| Q4 25 | -1.0% | -5.1% | ||
| Q3 25 | -11.1% | -8.3% | ||
| Q2 25 | -6.9% | 4.4% | ||
| Q1 25 | -27.4% | -10.3% | ||
| Q4 24 | -13.5% | -15.0% | ||
| Q3 24 | -13.9% | 10.8% | ||
| Q2 24 | -16.8% | 7.8% |
每股收益（稀释后）OFIXPEB
| Q1 26 | — | $-0.26 | ||
| Q4 25 | $-0.05 | $-0.22 | ||
| Q3 25 | $-0.57 | $-0.37 | ||
| Q2 25 | $-0.36 | $0.06 | ||
| Q1 25 | $-1.35 | $-0.37 | ||
| Q4 24 | $-0.76 | $-0.47 | ||
| Q3 24 | $-0.71 | $0.24 | ||
| Q2 24 | $-0.88 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $196.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $2.4B |
| 总资产 | $850.6M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPEB
| Q1 26 | — | $196.2M | ||
| Q4 25 | $82.0M | $184.2M | ||
| Q3 25 | $62.9M | $223.2M | ||
| Q2 25 | $65.6M | $256.1M | ||
| Q1 25 | $58.0M | $208.1M | ||
| Q4 24 | $83.2M | $206.7M | ||
| Q3 24 | $30.1M | $134.0M | ||
| Q2 24 | $26.4M | $101.7M |
总债务OFIXPEB
| Q1 26 | — | — | ||
| Q4 25 | — | $2.1B | ||
| Q3 25 | $157.2M | $2.2B | ||
| Q2 25 | $157.0M | $2.2B | ||
| Q1 25 | $156.9M | $2.2B | ||
| Q4 24 | $157.0M | $2.2B | ||
| Q3 24 | $118.5M | $2.2B | ||
| Q2 24 | $118.0M | $2.2B |
股东权益OFIXPEB
| Q1 26 | — | $2.4B | ||
| Q4 25 | $450.0M | $2.5B | ||
| Q3 25 | $442.5M | $2.5B | ||
| Q2 25 | $458.3M | $2.6B | ||
| Q1 25 | $458.3M | $2.6B | ||
| Q4 24 | $503.1M | $2.7B | ||
| Q3 24 | $525.9M | $2.8B | ||
| Q2 24 | $546.0M | $2.7B |
总资产OFIXPEB
| Q1 26 | — | $5.3B | ||
| Q4 25 | $850.6M | $5.3B | ||
| Q3 25 | $832.6M | $5.6B | ||
| Q2 25 | $837.2M | $5.7B | ||
| Q1 25 | $823.1M | $5.7B | ||
| Q4 24 | $893.3M | $5.7B | ||
| Q3 24 | $867.9M | $5.7B | ||
| Q2 24 | $882.0M | $5.7B |
负债/权益比OFIXPEB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.86× | ||
| Q3 25 | 0.36× | 0.89× | ||
| Q2 25 | 0.34× | 0.85× | ||
| Q1 25 | 0.34× | 0.85× | ||
| Q4 24 | 0.31× | 0.83× | ||
| Q3 24 | 0.23× | 0.80× | ||
| Q2 24 | 0.22× | 0.80× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $114.5M |
| 自由现金流率自由现金流/营收 | 7.6% | 33.1% |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXPEB
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $249.7M | ||
| Q3 25 | $12.4M | $77.6M | ||
| Q2 25 | $11.6M | $90.5M | ||
| Q1 25 | $-18.4M | $50.3M | ||
| Q4 24 | $23.7M | $275.0M | ||
| Q3 24 | $11.7M | $76.1M | ||
| Q2 24 | $9.0M | $83.7M |
自由现金流OFIXPEB
| Q1 26 | — | $114.5M | ||
| Q4 25 | $16.8M | $152.3M | ||
| Q3 25 | $2.5M | $6.8M | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | $146.3M | ||
| Q3 24 | $6.3M | $-24.8M | ||
| Q2 24 | $-360.0K | — |
自由现金流率OFIXPEB
| Q1 26 | — | 33.1% | ||
| Q4 25 | 7.6% | 43.6% | ||
| Q3 25 | 1.2% | 1.7% | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | 43.3% | ||
| Q3 24 | 3.2% | -6.1% | ||
| Q2 24 | -0.2% | — |
资本支出强度OFIXPEB
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 27.9% | ||
| Q3 25 | 4.8% | 17.7% | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | 38.1% | ||
| Q3 24 | 2.7% | 24.9% | ||
| Q2 24 | 4.7% | — |
现金转化率OFIXPEB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 2.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PEB
| Room | $214.5M | 62% |
| Food and beverage | $91.1M | 26% |
| Other | $40.0M | 12% |
